WO2002061076A1 - Adiponectin-associated protein - Google Patents
Adiponectin-associated protein Download PDFInfo
- Publication number
- WO2002061076A1 WO2002061076A1 PCT/JP2002/000844 JP0200844W WO02061076A1 WO 2002061076 A1 WO2002061076 A1 WO 2002061076A1 JP 0200844 W JP0200844 W JP 0200844W WO 02061076 A1 WO02061076 A1 WO 02061076A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- amino acid
- acid sequence
- adiponectin
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/467,102 US20050074762A1 (en) | 2001-02-01 | 2002-02-01 | Adiponectin-associated protein |
CA002437021A CA2437021A1 (en) | 2001-02-01 | 2002-02-01 | Adiponectin-associated protein |
JP2002561633A JPWO2002061076A1 (ja) | 2001-02-01 | 2002-02-01 | アディポネクチン関連蛋白質 |
EP02710470A EP1365022A4 (en) | 2001-02-01 | 2002-02-01 | ADIPONECTIN-ASSOCIATED PROTEIN |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001025962 | 2001-02-01 | ||
JP2001-25962 | 2001-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002061076A1 true WO2002061076A1 (en) | 2002-08-08 |
Family
ID=18890865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/000844 WO2002061076A1 (en) | 2001-02-01 | 2002-02-01 | Adiponectin-associated protein |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050074762A1 (ja) |
EP (1) | EP1365022A4 (ja) |
JP (1) | JPWO2002061076A1 (ja) |
CA (1) | CA2437021A1 (ja) |
WO (1) | WO2002061076A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099319A1 (fr) * | 2002-05-24 | 2003-12-04 | Japan Science And Technology Agency | Medicament preventif/curatif pour l'arteriosclerose |
WO2004022596A1 (en) * | 2002-09-05 | 2004-03-18 | Komed Co., Ltd. | Monoclonal antibody against adiponectin, preparation method and use thereof |
WO2004063711A2 (en) * | 2003-01-09 | 2004-07-29 | Beth Israel Deaconess Medical Center, Inc. | Use of adiponectin to diagnose and treat malignancy |
WO2005042007A1 (ja) * | 2003-11-04 | 2005-05-12 | Sankyo Company, Limited | 抗腫瘍剤 |
US7420038B2 (en) * | 2004-03-31 | 2008-09-02 | New York University | Compositions for controlling hair growth |
US8632990B2 (en) | 2005-12-07 | 2014-01-21 | Siemens Healthcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnosis and therapeutics |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
US7659125B2 (en) | 2003-03-24 | 2010-02-09 | Mitsubishi Kagaku Latron, Inc. | Latex reagent for adiponectin analysis and method of adiponectin analysis |
US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US20100129288A1 (en) * | 2005-06-28 | 2010-05-27 | Elior Peles | Gliomedin, Fragments Thereof and Methods of Using Same |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
CN112574306B (zh) * | 2020-12-17 | 2023-05-05 | 武汉华美生物工程有限公司 | 脂联素单克隆抗体、抗体对及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780611A (en) * | 1995-09-15 | 1998-07-14 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US20020095031A1 (en) * | 1999-05-04 | 2002-07-18 | Nehls Michael C. | Novel human polynucleotides and polypeptides encoded thereby |
EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
-
2002
- 2002-02-01 CA CA002437021A patent/CA2437021A1/en not_active Abandoned
- 2002-02-01 EP EP02710470A patent/EP1365022A4/en not_active Withdrawn
- 2002-02-01 US US10/467,102 patent/US20050074762A1/en not_active Abandoned
- 2002-02-01 WO PCT/JP2002/000844 patent/WO2002061076A1/ja not_active Application Discontinuation
- 2002-02-01 JP JP2002561633A patent/JPWO2002061076A1/ja active Pending
Non-Patent Citations (3)
Title |
---|
MAEDA K. ET AL.: "cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1)", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 221, no. 2, 1996, pages 286 - 289, XP000612064 * |
MATSUZAWA Y. ET AL.: "Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances", ANN. N.Y. ACAD. SCI., vol. 892, 1999, pages 146 - 154, XP002951099 * |
See also references of EP1365022A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099319A1 (fr) * | 2002-05-24 | 2003-12-04 | Japan Science And Technology Agency | Medicament preventif/curatif pour l'arteriosclerose |
US7419955B2 (en) | 2002-05-24 | 2008-09-02 | Japan Science And Technology Agency | Method for treating arteriosclerosis |
WO2004022596A1 (en) * | 2002-09-05 | 2004-03-18 | Komed Co., Ltd. | Monoclonal antibody against adiponectin, preparation method and use thereof |
WO2004063711A2 (en) * | 2003-01-09 | 2004-07-29 | Beth Israel Deaconess Medical Center, Inc. | Use of adiponectin to diagnose and treat malignancy |
WO2004063711A3 (en) * | 2003-01-09 | 2004-09-16 | Beth Israel Hospital | Use of adiponectin to diagnose and treat malignancy |
WO2005042007A1 (ja) * | 2003-11-04 | 2005-05-12 | Sankyo Company, Limited | 抗腫瘍剤 |
US7863243B2 (en) | 2003-11-04 | 2011-01-04 | Sankyo Company, Limited | Anti-tumor agent |
US7420038B2 (en) * | 2004-03-31 | 2008-09-02 | New York University | Compositions for controlling hair growth |
US7705126B2 (en) | 2004-03-31 | 2010-04-27 | New York University | Compositions for controlling hair growth |
US8632990B2 (en) | 2005-12-07 | 2014-01-21 | Siemens Healthcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnosis and therapeutics |
US8846346B2 (en) | 2005-12-07 | 2014-09-30 | Siemens Healthcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnosis and therapeutics |
Also Published As
Publication number | Publication date |
---|---|
US20050074762A1 (en) | 2005-04-07 |
EP1365022A4 (en) | 2004-04-28 |
CA2437021A1 (en) | 2002-08-08 |
JPWO2002061076A1 (ja) | 2004-06-03 |
EP1365022A1 (en) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002061076A1 (en) | Adiponectin-associated protein | |
WO2004043382A3 (en) | Enhanced variants of erythropoietin and methods of use | |
WO2003048202A3 (en) | Nf-kappab activating genes | |
WO2003012105A3 (en) | Vegf isoform | |
EP1308459A3 (en) | Full-length cDNA sequences | |
EP1803733A3 (en) | Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation | |
AU2002303214A1 (en) | Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof | |
IL135687A0 (en) | A novel human checkpoint kinase, hcds1, compositions and methods | |
WO2002072616A3 (en) | Transfection complexes | |
CA2281206A1 (en) | Geranyl diphosphate synthase genes | |
AU8748198A (en) | Carcinostatic agents | |
WO2002092758A3 (en) | Gastrokines and derived peptides including inhibitors | |
EP0816504A3 (en) | Platelet activating factor acetylhdrolase, and gene thereof | |
WO2000037613A3 (en) | Human akt-3 | |
AU2003264535A1 (en) | Tumor antigen protein and utilization thereof | |
ATE375390T1 (de) | G-protein-gekoppelter rezeptor-ähnliche proteine | |
EP1568775A4 (en) | CANCER ASSOCIATED GEN | |
WO2003022300A1 (fr) | Remedes prophylactiques et curatifs contre les maladies des os et des articulations | |
AU2640299A (en) | Genomic gene encoding hm1.24 antigen protein and promoter thereof | |
WO2005105838A3 (en) | Ion channel | |
WO2003018806A1 (fr) | Nouveau gene humain bmcc1 | |
WO2003038095A3 (fr) | Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques | |
WO2005019407A3 (en) | Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseases | |
EP1158052A4 (en) | BETA-PRIMEVEROSIDASDE GENE | |
WO2004013167A3 (en) | Purified polypeptides from enterococcus faecalis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200302911 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002561633 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2437021 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002710470 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002710470 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10467102 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002710470 Country of ref document: EP |